Lindqvist-type Polyoxometalates Act as Anti-breast Cancer Drugs via Mitophagy-induced Apoptosis

Abstract

Objective

Lindqvist-type polyoxometalates (POMs) exhibit potential antitumor activities. This study aimed to examine the effects of Lindqvist-type POMs against breast cancer and the underlying mechanism.

Methods

Using different cancer cell lines, the present study evaluated the antitumor activities of POM analogues that were modified at the body skeleton based on molybdenum-vanadium-centered negative oxygen ion polycondensations with different side strains. Cell colony formation assay, autophagy detection, mitochondrial observation, qRT-PCR, Western blotting, and animal model were used to evaluate the antitumor activities of POMs against breast cancer cells and the related mechanism.

Results

MO-4, a Lindqvist-type POM linking a proline at its side strain, was selected for subsequent experiments due to its low half maximal inhibitory concentration in the inhibition of proliferation of breast cancer cells. It was found that MO-4 induced the apoptosis of multiple types of breast cancer cells. Mechanistically, MO-4 activated intracellular mitophagy by elevating mitochondrial reactive oxygen species (ROS) levels and resulting in apoptosis. In vivo, breast tumor growth and distant metastasis were significantly reduced following MO-4 treatment.

Conclusion

Collectively, the results of the present study demonstrated that the novel Lindqvist-type POM MO-4 may exhibit potential in the treatment of breast cancer.

References

[1] CaiZ, LiuQ. Understanding the Global Cancer Statistics 2018: implications for cancer control. Sci China Life Sci, 2021, 64(6): 1017-1020

[2] AghaeiM, KhanahmadH, AghaeiS, et al.. The role of Bax in the apoptosis of Leishmania-infected macrophages. Microb Pathog, 2020, 139: 103892

[3] RaphaelMJ, BiagiJJ, KongW, et al.. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat, 2016, 160(1): 17-28

[4] RossiL, MazzaraC, PaganiO. Diagnosis and treatment of breast cancer in young women. Curr Treat Options Oncol, 2019, 20(12): 86

[5] AnastasiadiZ, LianosGD, IgnatiadouE, et al.. Breast cancer in young women: an overview. Updates Surg, 2017, 69(3): 313-317

[6] LeemasawatK, PhrommintikulA, ChattipakornSC, et al.. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci, 2020, 77(8): 1571-1589

[7] Van RompuyLS, Parac-VogtTN. Interactions between polyoxometalates and biological systems: from drug design to artificial enzymes. Curr Opin Biotechnol, 2019, 58: 92-99

[8] WangL, YuK, ZhouBB, et al.. The inhibitory effects of a new cobalt-based polyoxometalate on the growth of human cancer cells. Dalton Trans, 2014, 43(16): 6070-6078

[9] JoshiA, GuptaR, VaghasiyaK, et al.. In vitro anti-tumoral and antibacterial activity of an octamolybdate cluster-based hybrid solid incorporated with a copper picolinate complex. ACS Appl Bio Mater, 2020, 3(7): 4025-4035

[10] ZhangX, ZhangT, GuoS, et al.. In vitro antifungal activity and mechanism of Ag3PW12O40 composites against Candida Species. Molecules, 2020, 25(24): 6012

[11] WangS, SunW, HuQ, et al.. Synthesis and evaluation of pyridinium polyoxometalates as anti-HIV-1 agents. Bioorg Med Chem Lett, 2017, 27(11): 2357-2359

[12] YanagieH, OgataA, MitsuiS, et al.. Anticancer activity of polyoxomolybdate. Biomed Pharmacother, 2006, 60(7): 349-352

[13] HuangX, GuoH, WangL, et al.. Engineered microorganism-based delivery systems for targeted cancer therapy: a narrative review. Biomater Transl, 2022, 3(3): 201-212

[14] TagliaviniV, HonischC, SerratìS, et al.. Enhancing the biological activity of polyoxometalate-peptide nanofibrils by spacer design. RSC Adv, 2021, 11(9): 4952-4957

[15] Pérez-ÁlvarezL, Ruiz-RubioL, ArtetxeB, et al.. Chitosan nanogels as nanocarriers of polyoxometalates for breast cancer therapies. Carbohydr Polym, 2019, 213: 159-167

[16] HuJ, TanSK, LimMGL, et al.. Identification of a Wells-Dawson polyoxometalate-based AP-2gamma inhibitor with pro-apoptotic activity. Biochem J, 2018, 475(11): 1965-1977

[17] BijelicA, AurelianoM, RompelA. Polyoxometalates as potential next-generation metallodrugs in the combat against cancer. Angew Chem Int Ed Engl, 2019, 58(10): 2980-2999

[18] LiJ, WangX, WangY, et al.. Highly dispersed Ni, N-doped Mo2C nanoparticles prepared from organic-derived polyoxomolybdates for efficient electrocatalytic hydrogen evolution. Int J Hydrogen Enegr, 2022, 47(67): 28915-28923

[19] ZhouC, DongX, WangM. Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity. Cell Insight, 2022, 1(4): 100045

[20] ZhouX, WuX, QinL, et al.. Anti-breast cancer effect of 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione in vivo and in vitro through MAPK signaling pathway. Drug Des Devel Ther, 2020, 14: 2667-2684

[21] JiaH, WangX, LiuW, et al.. Cimicifuga dahurica extract inhibits the proliferation, migration and invasion of breast cancer cells MDA-MB-231 and MCF-7 in vitro and in vivo. J Ethnopharmacol, 2021, 277: 114057

[22] YaoC, WengJ, FengL, et al.. SIPA1 enhances aerobic glycolysis through HIF-2alpha pathway to promote breast cancer metastasis. Front Cell Dev Biol, 2021, 9: 779169

[23] ChuangKC, ChangCR, ChangSH, et al.. Imiquimod-induced ROS production disrupts the balance of mitochondrial dynamics and increases mitophagy in skin cancer cells. J Dermatol Sci, 2020, 98(3): 152-162

[24] OgataA, MitsuiS, YanagieH, et al.. A novel anti-tuor agent, polyoxomolybdate induces apoptotic cell death in AsPC-1 human pancreatic cancer cells. Biomed Pharmacother, 2005, 59(5): 240-244

[25] KarimianA, AhmadiY, YousefiB. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst), 2016, 42: 63-71

[26] OgataA, YanagieH, IshikawaE, et al.. Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models. Br J Cancer, 2008, 98(2): 399-409

[27] HanXJ, YangZJ, JiangLP. Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. Int J Oncol, 2015, 46(2): 691-700

[28] ZhengY, GanH, ZhaoY, et al.. Self-assembly and antitumor activity of a polyoxovanadate-based coordination nanocag. Chemistry, 2019, 25(67): 15326-15332

[29] YanagieH, OgataA, MitsuiS, et al.. Anticancer activity of polyoxomolybdate. Biomed Pharmacother, 2006, 60(7): 349-352

[30] GlabJ A, CaoZ, PuthalakathH. Bcl-2 family proteins, beyond the veil. Int Rev Cell Mol Biol, 2020, 351: 1-22

[31] Castro-CastilloV, Suarez-RozasC, Castro-LoizaN, et al.. Annulation of substituted anthracene-9,10-diones yields promising selectively antiproliferative compounds. Eur J Med Chem, 2013, 62: 688-692

[32] XiongS, MuT, WangG. Mitochondria-mediated apoptosis in mammals. Protein Cell, 2014, 5(10): 37-49

[33] BirkinshawR, CzabotarP. The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation. Semin Cell Dev Biol, 2017, 72: 152-162

[34] ArayaLE, SoniIV, HardyJA, et al.. Deorphanizing Caspase-3 and Caspase-9 substrates in and out of apoptosis with deep substrate profiling. ACS Chem Biol, 2021, 16(11): 2280-2296

[35] LiuJ, YaoY, DingH, et al.. Oxymatrine triggers apoptosis by regulating Bcl-2 family proteins and activating caspase-3/caspase-9 pathway in human leukemia HL-60 cells. Tumor Biol, 2014, 35(6): 5409-5415

[36] WeiA, FuB, WangY, et al.. Involvement of NO and ROS in sulfur dioxide induced guard cells apoptosis in Tagetes erecta. Ecotoxicol Environ Saf, 2015, 114: 198-203

[37] LeonIE, PorroV, AstradaS, et al.. Polyoxometalates as antitumor agents: Bioactivity of a new polyoxometalate with copper on a human osteosarcoma model. Chem Biol Interact, 2014, 222: 87-96

[38] YooSM, JungYK. A molecular approach to mitophagy and mitochondrial dynamics. Mol Cells, 2018, 41(1): 18-26

[39] MohamadNE, AbuN, YeapSK, et al.. Bromelain enhances the anti-tumor effects of cisplatin on 4T1 breast tumor model in vivo. Integr Cancer Ther, 2019, 18: 1534735419880258